United Therapeutics agreed to acquire Thymmune Therapeutics for $140 million upfront, with up to $160 million more tied to milestones, to expand its regenerative cell-therapy pipeline focused on the thymus. Thymmune’s platform converts human-induced pluripotent stem cells into thymic cells designed to mature in the body and restore T-cell function. The near-term clinical focus is congenital athymia, an ultra-rare condition in which patients lack a thymus and face fatal infections and immune dysregulation. In animals, Thymmune’s preclinical candidate THY-100 induced a “neo-thymus,” and the deal includes additional payment potential through 2031 tied to clinical and regulatory progress. United’s plan extends beyond congenital athymia, with its roadmap described to include transplant tolerance and serious immune-mediated diseases—an ambition that could broaden the addressable market if early proof-of-concept holds.